Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Length dependent activation of OAS proteins by dsRNA.

Wang Y, Holleufer A, Gad HH, Hartmann R.

Cytokine. 2019 Oct 17;126:154867. doi: 10.1016/j.cyto.2019.154867. [Epub ahead of print]

PMID:
31629990
2.

Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines.

Ye L, Ohnemus A, Ong LC, Gad HH, Hartmann R, Lycke N, Staeheli P.

J Virol. 2019 Nov 13;93(23). pii: e01262-19. doi: 10.1128/JVI.01262-19. Print 2019 Dec 1.

PMID:
31511392
3.

Identification of an IRF3 variant and defective antiviral interferon responses in a patient with severe influenza.

Thomsen MM, Jørgensen SE, Storgaard M, Kristensen LS, Gjedsted J, Christiansen M, Gad HH, Hartmann R, Mogensen TH.

Eur J Immunol. 2019 Nov;49(11):2111-2114. doi: 10.1002/eji.201848083. No abstract available.

PMID:
31250433
4.

Defective interferon priming and impaired antiviral responses in a patient with an IRF7 variant and severe influenza.

Thomsen MM, Jørgensen SE, Gad HH, Storgaard M, Gjedsted J, Christiansen M, Hartmann R, Mogensen TH.

Med Microbiol Immunol. 2019 Dec;208(6):869-876. doi: 10.1007/s00430-019-00623-8. Epub 2019 Jun 6.

PMID:
31172279
5.

The Influence of the rs30461 Single Nucleotide Polymorphism on IFN-λ1 Activity and Secretion.

Møhlenberg M, Gad HH, Hartmann R.

J Interferon Cytokine Res. 2019 Oct;39(10):661-667. doi: 10.1089/jir.2019.0051. Epub 2019 May 22.

PMID:
31120365
6.

Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin.

Ye L, Schnepf D, Becker J, Ebert K, Tanriver Y, Bernasconi V, Gad HH, Hartmann R, Lycke N, Staeheli P.

Nat Immunol. 2019 May;20(5):593-601. doi: 10.1038/s41590-019-0345-x. Epub 2019 Mar 18.

PMID:
30886417
7.

Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ.

Jacobs S, Wavreil F, Schepens B, Gad HH, Hartmann R, Rocha-Pereira J, Neyts J, Saelens X, Michiels T.

J Interferon Cytokine Res. 2018 Nov;38(11):469-479. doi: 10.1089/jir.2018.0066. Epub 2018 Oct 18.

8.

IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission.

Klinkhammer J, Schnepf D, Ye L, Schwaderlapp M, Gad HH, Hartmann R, Garcin D, Mahlakõiv T, Staeheli P.

Elife. 2018 Apr 13;7. pii: e33354. doi: 10.7554/eLife.33354.

9.

The interferon-stimulated gene product oligoadenylate synthetase-like protein enhances replication of Kaposi's sarcoma-associated herpesvirus (KSHV) and interacts with the KSHV ORF20 protein.

Bussey KA, Lau U, Schumann S, Gallo A, Osbelt L, Stempel M, Arnold C, Wissing J, Gad HH, Hartmann R, Brune W, Jänsch L, Whitehouse A, Brinkmann MM.

PLoS Pathog. 2018 Mar 2;14(3):e1006937. doi: 10.1371/journal.ppat.1006937. eCollection 2018 Mar.

10.

Defective RNA sensing by RIG-I in severe influenza virus infection.

Jørgensen SE, Christiansen M, Ryø LB, Gad HH, Gjedsted J, Staeheli P, Mikkelsen JG, Storgaard M, Hartmann R, Mogensen TH.

Clin Exp Immunol. 2018 Jun;192(3):366-376. doi: 10.1111/cei.13120. Epub 2018 Mar 24.

11.

IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.

Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R, Wack A.

EMBO Mol Med. 2016 Sep 1;8(9):1099-112. doi: 10.15252/emmm.201606413. Print 2016 Sep.

12.

Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses.

Holm CK, Rahbek SH, Gad HH, Bak RO, Jakobsen MR, Jiang Z, Hansen AL, Jensen SK, Sun C, Thomsen MK, Laustsen A, Nielsen CG, Severinsen K, Xiong Y, Burdette DL, Hornung V, Lebbink RJ, Duch M, Fitzgerald KA, Bahrami S, Mikkelsen JG, Hartmann R, Paludan SR.

Nat Commun. 2016 Feb 19;7:10680. doi: 10.1038/ncomms10680.

13.

Functional IRF3 deficiency in a patient with herpes simplex encephalitis.

Andersen LL, Mørk N, Reinert LS, Kofod-Olsen E, Narita R, Jørgensen SE, Skipper KA, Höning K, Gad HH, Østergaard L, Ørntoft TF, Hornung V, Paludan SR, Mikkelsen JG, Fujita T, Christiansen M, Hartmann R, Mogensen TH.

J Exp Med. 2015 Aug 24;212(9):1371-9. doi: 10.1084/jem.20142274. Epub 2015 Jul 27.

14.

Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells.

Lauber C, Vieyres G, Terczyńska-Dyla E, Anggakusuma, Dijkman R, Gad HH, Akhtar H, Geffers R, Vondran FW, Thiel V, Kaderali L, Pietschmann T, Hartmann R.

Genes Immun. 2015 Sep;16(6):414-21. doi: 10.1038/gene.2015.23. Epub 2015 Jun 11.

PMID:
26066369
15.

A conserved sugar bridge connected to the WSXWS motif has an important role for transport of IL-21R to the plasma membrane.

Siupka P, Hamming OT, Kang L, Gad HH, Hartmann R.

Genes Immun. 2015 Sep;16(6):405-13. doi: 10.1038/gene.2015.22. Epub 2015 Jun 4.

PMID:
26043171
16.

Structural and functional analysis reveals that human OASL binds dsRNA to enhance RIG-I signaling.

Ibsen MS, Gad HH, Andersen LL, Hornung V, Julkunen I, Sarkar SN, Hartmann R.

Nucleic Acids Res. 2015 May 26;43(10):5236-48. doi: 10.1093/nar/gkv389. Epub 2015 Apr 29.

17.

Rapid Uptake and Inhibition of Viral Propagation by Extracellular OAS1.

Thavachelvam K, Gad HH, Ibsen MS, Desprès P, Hokland M, Hartmann R, Kristiansen H.

J Interferon Cytokine Res. 2015 May;35(5):359-66. doi: 10.1089/jir.2014.0140. Epub 2014 Dec 17.

PMID:
25517543
18.

The 2'-5'-oligoadenylate synthetase 3 enzyme potently synthesizes the 2'-5'-oligoadenylates required for RNase L activation.

Ibsen MS, Gad HH, Thavachelvam K, Boesen T, Desprès P, Hartmann R.

J Virol. 2014 Dec;88(24):14222-31. doi: 10.1128/JVI.01763-14. Epub 2014 Oct 1.

19.

Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component.

Bouraï M, Lucas-Hourani M, Gad HH, Drosten C, Jacob Y, Tafforeau L, Cassonnet P, Jones LM, Judith D, Couderc T, Lecuit M, André P, Kümmerer BM, Lotteau V, Desprès P, Tangy F, Vidalain PO.

J Virol. 2012 Mar;86(6):3121-34. doi: 10.1128/JVI.06390-11. Epub 2012 Jan 18.

20.

The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities.

Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R.

J Interferon Cytokine Res. 2011 Jan;31(1):41-7. doi: 10.1089/jir.2010.0107. Epub 2010 Dec 12. Review.

PMID:
21142819
21.

The structure of human interferon lambda and what it has taught us.

Gad HH, Hamming OJ, Hartmann R.

J Interferon Cytokine Res. 2010 Aug;30(8):565-71. doi: 10.1089/jir.2010.0062. Review.

PMID:
20712454
22.

Lambda Interferons: New Cytokines with Old Functions.

Hamming OJ, Gad HH, Paludan S, Hartmann R.

Pharmaceuticals (Basel). 2010 Mar 25;3(4):795-809. Review.

23.

Selection of a novel and highly specific tumor necrosis factor alpha (TNFalpha) antagonist: insight from the crystal structure of the antagonist-TNFalpha complex.

Byla P, Andersen MH, Holtet TL, Jacobsen H, Munch M, Gad HH, Thøgersen HC, Hartmann R.

J Biol Chem. 2010 Apr 16;285(16):12096-100. doi: 10.1074/jbc.M109.063305. Epub 2010 Feb 23.

24.

Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family.

Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R.

J Biol Chem. 2009 Jul 31;284(31):20869-75. doi: 10.1074/jbc.M109.002923. Epub 2009 May 20.

25.

Human interferon-lambda3 is a potent member of the type III interferon family.

Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R.

Genes Immun. 2009 Mar;10(2):125-31. doi: 10.1038/gene.2008.87. Epub 2008 Nov 6.

PMID:
18987645

Supplemental Content

Support Center